Free Trial

Nisa Investment Advisors LLC Has $2.60 Million Stock Position in STERIS plc (NYSE:STE)

STERIS logo with Medical background

Nisa Investment Advisors LLC cut its stake in STERIS plc (NYSE:STE - Free Report) by 10.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,454 shares of the medical equipment provider's stock after selling 1,273 shares during the period. Nisa Investment Advisors LLC's holdings in STERIS were worth $2,596,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its position in shares of STERIS by 19.4% during the 4th quarter. Jones Financial Companies Lllp now owns 757 shares of the medical equipment provider's stock valued at $156,000 after purchasing an additional 123 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of STERIS in the fourth quarter worth $9,895,000. Citizens Financial Group Inc. RI grew its stake in shares of STERIS by 5.9% in the fourth quarter. Citizens Financial Group Inc. RI now owns 975 shares of the medical equipment provider's stock worth $201,000 after acquiring an additional 54 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of STERIS by 41.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,117 shares of the medical equipment provider's stock worth $230,000 after acquiring an additional 330 shares during the last quarter. Finally, LBP AM SA grew its stake in shares of STERIS by 151.3% in the fourth quarter. LBP AM SA now owns 26,519 shares of the medical equipment provider's stock worth $5,451,000 after acquiring an additional 15,965 shares during the last quarter. Institutional investors own 94.69% of the company's stock.

STERIS Trading Down 0.6%

Shares of STERIS stock traded down $1.36 during trading on Wednesday, hitting $227.48. 552,901 shares of the company were exchanged, compared to its average volume of 554,793. The firm has a market capitalization of $22.38 billion, a P/E ratio of 36.69 and a beta of 0.92. STERIS plc has a 1-year low of $200.98 and a 1-year high of $252.79. The firm's fifty day moving average price is $238.71 and its 200 day moving average price is $226.27. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.96 and a quick ratio of 1.39.

STERIS (NYSE:STE - Get Free Report) last posted its earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.15. The company had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.47 billion. STERIS had a return on equity of 14.21% and a net margin of 11.26%. The company's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the previous year, the company earned $2.58 EPS. As a group, sell-side analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 26th. Investors of record on Tuesday, June 10th were given a $0.57 dividend. The ex-dividend date of this dividend was Tuesday, June 10th. This represents a $2.28 annualized dividend and a dividend yield of 1.00%. STERIS's dividend payout ratio is presently 36.77%.

Insider Activity at STERIS

In related news, CEO Daniel A. Carestio sold 17,626 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $242.56, for a total value of $4,275,362.56. Following the completion of the transaction, the chief executive officer directly owned 51,385 shares in the company, valued at approximately $12,463,945.60. The trade was a 25.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Cary L. Majors sold 12,828 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $250.08, for a total value of $3,208,026.24. Following the completion of the transaction, the senior vice president owned 11,372 shares of the company's stock, valued at $2,843,909.76. This represents a 53.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on STE. Wall Street Zen upgraded shares of STERIS from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 14th. Stephens restated an "overweight" rating and issued a $250.00 target price on shares of STERIS in a research note on Thursday, May 15th. JMP Securities boosted their target price on shares of STERIS from $265.00 to $280.00 and gave the company a "market outperform" rating in a research note on Friday, May 16th. Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a report on Monday, April 7th. Finally, Jefferies Financial Group started coverage on STERIS in a report on Thursday, May 29th. They set a "hold" rating and a $263.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $266.50.

Check Out Our Latest Stock Report on STE

STERIS Company Profile

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Further Reading

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Should You Invest $1,000 in STERIS Right Now?

Before you consider STERIS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.

While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines